Skip to content
Annika Bansal – Lifestyle
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
August 4, 2026
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
August 4, 2026
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
August 3, 2026
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
July 2, 2026
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
June 29, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
Why the Crystal Flush Website Recommends a 90-Day Protocol for Lasting Nail Health
May 26, 2026
Crystal Flush Customer Complaints Explained: Are You Giving It the Full 90 Days?
May 22, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 5, 2026
1
2
3
Next Page
→